Concepedia

Janmejay Singh

JS

Statistics

Publications

13

Citations

347

H-Index

11

Active since

2022

Affiliations

Translational Health Science and Technology Institute(Current)

All India Institute of Medical Sciences

ESIC Hospital

Biological E (India)

Institute of Genomics and Integrative Biology

Janmejay Singh is an author at Translational Health Science and Technology Institute specializing in immunology, infectious diseases, and veterinary medicine.

ORCID

Publications per year

2022–2024

13

Publications

13

Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials

Subhash Thuluva, Vikram Paradkar, Subba Reddy Gunneri et al. · EBioMedicine · 2022 · 74 citations · Full text

, , +16

Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months

Guruprasad R. Medigeshi, Gaurav Batra, Deepika Rathna Murugesan et al. · EBioMedicine · 2022 · 58 citations · Full text

, , +17

Safety, tolerability and immunogenicity of Biological E’s CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study

Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri et al. · Vaccine · 2022 · 33 citations

, , +15

Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial

Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri et al. · Human Vaccines & Immunotherapeutics · 2023 · 32 citations · Full text

, , +17

Pre-existing antibody levels negatively correlate with antibody titers after a single dose of BBV152 vaccination

Suman R. Das, Janmejay Singh, Heena Shaman et al. · Nature Communications · 2022 · 23 citations · Full text

, , +17

1–5 of 13